


## **Data Sheet**

## WWW. UREIKO-CHEM. COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

 $\begin{tabular}{lll} \textbf{Product Name} & :RP-6306 \\ \textbf{Cat.No.} & :URK-V2353 \\ \textbf{CAS No.} & :2719793-90-3 \\ \textbf{Molecular Formula} & :C_{18}H_{20}N_4O_2 \\ \textbf{Molecular Weight} & :324.384 \\ \textbf{Target} & :Wee1 \\ \end{tabular}$ 

Solubility :



## **Biological Activity**

RP-6306 (RP6306) is a first-in-class, potent and selective, orally available inhibitor of PKMYT1 with IC50 of 2.4 nM, displays less potency (>35-fold) against EphA1-2, and EphB2-4, and Wee1.

RP-6306 inhibits the phosphorylation of CDK1 Thr14 in vivo in tumor tissue and inhibits CCNE1-amplified tumor cell growth in several preclinical xenograft models.

PKMYT1 is an important regulator of CDK1 phosphorylation and is a compelling therapeutic target for the treatment of certain types of DNA damage response cancers due to its established synthetic lethal relationship with CCNE1 amplification.

PKMYT1 is a member of the Wee-kinase family protein kinases, PKMYT1 is involved in G2/M checkpoint regulation of the cell cycle.

## References

1. Janek Szychowski, et al. Discovery of an orally bioavailable and selective PKMYT1 inhibitor RP-6306. ChemRxiv. DOI 10.26434/chemrxiv-2022-2g6m6.

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!